Proteasome Targeting with Carfilzomib Induces Reactive Oxygen Species-Mediated Apoptosis in Hepatoblastoma
Cells · 09.05.2026 · 15 (10) · 864
DOI: 10.3390/cells15100864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 09.05.2026. Verfasst von Elena Johanna Weigl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Lindwurmstreet 2a, 80337 Munich, Germany. Hauptthemen laut MEDLINE: Hepatoblastoma, Reactive Oxygen Species, Apoptosis, Oligopeptides. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatoblastoma (HB) is the most common malignant liver tumor in children, yet therapeutic options remain largely confined to conventional chemotherapy. To identify novel therapeutic targets, we performed gene set enrichment analysis on three publicly available HB datasets and found consistent activation of the proteasome pathway, with marked overexpression of the β5 proteolytic subunit encoded by PSMB5. High PSMB5 expression was associated with poor survival in adult hepatocellular carcinoma, highlighting the proteasome as a candidate for therapeutic vulnerability. Targeting the β5 proteolytic subunit with its selective inhibitor carfilzomib in HB patient-derived xenograft (PDX) models resulted in dose-dependent reductions in cell viability, proliferation, and clonogenic growth, accompanied by induction of apoptosis. Importantly, carfilzomib retained efficacy in three-dimensional PDX cultures, underscoring its activity in physiologically relevant tumor models. Bioinformatic analyses revealed that carfilzomib activates apoptosis and reactive oxygen species (ROS) signaling. Validation experiments in HB cells demonstrated increased ROS levels, with ROS induction correlating with drug sensitivity. Notably, pharmacological scavenging of ROS completely abrogated carfilzomib-induced cytotoxicity, establishing oxidative stress as a key mediator of therapeutic response. Together, these findings identify PSMB5 as a therapeutically actionable target in HB and support proteasome inhibition as a promising precision medicine strategy in HB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Lindwurmstreet 2a, 80337 Munich, Germany.
- XenTech, 91000 Evry, France.
- Bicêtre Hospital, AP-HP Paris Saclay University, 94270 Le Kremlin-Bicêtre, France.
- Champions Oncology, Rockville, MD 20850, USA.
ORCID-Profile: Salih Demir, Stefano Cairo, Roland Kappler
Zitieren
APA
Weigl, E. J., Demir, S., Hotes, A., Indersie, E., Branchereau, S., Cairo, S., & Kappler, R. (2026). Proteasome Targeting with Carfilzomib Induces Reactive Oxygen Species-Mediated Apoptosis in Hepatoblastoma. Cells, 15(10), 864. https://doi.org/10.3390/cells15100864
Vancouver
Weigl EJ, Demir S, Hotes A, Indersie E, Branchereau S, Cairo S, et al. Proteasome Targeting with Carfilzomib Induces Reactive Oxygen Species-Mediated Apoptosis in Hepatoblastoma. Cells. 2026;15(10):864. doi:10.3390/cells15100864
BibTeX
@article{Weigl2026,
author = {Weigl, Elena Johanna and Demir, Salih and Hotes, Alina and Indersie, Emilie and Branchereau, Sophie and Cairo, Stefano and Kappler, Roland},
title = {Proteasome Targeting with Carfilzomib Induces Reactive Oxygen Species-Mediated Apoptosis in Hepatoblastoma},
journal = {Cells},
year = {2026},
volume = {15},
number = {10},
pages = {864},
doi = {10.3390/cells15100864}
}
EUVIMED